This Week Last Year in Medtech: March 12-18

Dexcom Fires Up the Diabetes Space by Winning CE Mark for G7

The Dexcom G7 CGM’s approval in Europe follows closely behind rival Senseonics winning FDA approval for a 180-day version of Eversense.

iRhythm’s Kevin King Set to Retire from Board

King was once the San Francisco-based company’s president and CEO. He had served on the company’s board since July 2012.

Getting Advanced Surgical Equipment into Hospitals Requires a New Mindset

Surgical equipment vendors and hospitals should no longer have us-versus-them relationships. They should embrace shared risks and rewards.

Can Better Therapeutics’s PDT Make a Dent in Type 2 Diabetes?

The company released favorable data from a pivotal study of its prescription digital therapeutic platform.

M&A, Data, & Big Approvals Are Defining Diabetes Tech in 2022

Glooko keeps the momentum going in diabetes tech by acquiring Diabnext, to expand its presence in Europe.

Japan Is the Next Stop for Guardant’s Liquid Biopsy Test

Japan’s Ministry of Health, Labour and Welfare has granted regulatory approval of the Guardant 360 CdX.

3 Healthcare Trends Medtech Will Master

The pandemic kickstarted three irreversible trends in care delivery that medical device companies like BD are already strategizing around.

How Will New Cybersecurity Law Impact Medtech?

The Strengthening American Cybersecurity Act, which President Biden has signed into law, requires hospitals to report cybersecurity incidents and ransomware payments. How will the new law impact medical device companies?